ADCs In Oncology Trials Webinar

Whether you are preparing to launch your first Antibody-drug conjugate (ADC) study or looking to optimize current programs, this session will deliver practical insights you can put into action immediately. ADCs are reshaping the future of oncology, bringing precision and potency together in ways that were only imagined a few decades ago. While the concept has existed since the 1980s, breakthroughs in antibody design, linker stability, and payload innovation have transformed ADCs into one of the most dynamic areas of cancer drug development today. In this presentation, a panel of clinical and medical experts will share real-world case studies and hard-won strategies for navigating the fast-moving ADC trial landscape.